Putting an End to
Dr. Paul O’Connor’s research offers hope
PA U L for new MS treatments.
O’C O N N O R Dr. Paul O’Connor remembers a patient who came into the Multiple Sclerosis
(MS) Clinic at St. Michael’s Hospital after she had experienced a number of
M.D., M.Sc., F.R.C.P.C. devastating problems caused by her MS. She was partially blind and unable to
walk properly. Today, she can see and can walk normally again because of
Division of Neurology, St. Michael’s Hospital advancements in research.
Director, MS Clinic, St. Michael’s Hospital “Her family and work life were falling apart because of her condition,”
says Dr. O’Connor. “Every day I see patients who face the same struggles
Professor, Division of Neurology,University that this young woman did, but research makes new treatments possible
so that people with MS can resume a normal life.”
Dr. Paul O’Connor is a highly-respected researcher who is well
National Scientific and Clinical Advisor, known in the MS community for his clinical work. He has been
treating people with MS for 25 years. Thanks to his leadership,
Multiple Sclerosis Society St. Michael’s Hospital is a world leader in developing new drugs
for MS, including Tysabri, the first new MS treatment in 10 years.
Past-President, Canadian Network of MS Clinics
“When I saw the devastation MS causes in people who have
their whole lives ahead of them, I was moved to act—
particularly because the mechanisms of the disease are a bit
mysterious and intellectually challenging,” says Dr. O’Connor.
Under Dr. O’Connor’s leadership, St. Michael’s has
become a global leader in caring for MS patients. The
Hospital has the largest MS clinic in North America and the
largest clinical trial and research centre in the world.
Dr. O’Connor works with investigators around the world to
find new therapies and treatment options for MS patients.
Dr. O’Connor is now leading a study that could mean
an easy and affordable way to help MS patients manage the
disease. He believes that Vitamin D may be able to slow
down brain damage from MS over time and is looking to
prove it in human clinical trials.
“We have made significant progress in treating earlier
forms of the disease, and we are now taking on the later and
more difficult progressive cases of the illness,” says
Dr. O’Connor. “We’re doing what we can to improve our
patients’ quality of life, but our ultimate goal is to stop
MS and reverse the devastating neurological damage that MS
RESEARCH PROGRAM – ST. MICHAEL’S HOSPITAL